https://www.prweb.com/releases/bill_sickert_joins_nulife_ventures/prweb16382404.htm
CARLSBAD, Calif. (PRWEB)June 17, 2019
The medical technology consumer advocate Bill Sickert joins the ultimate technology partner NuLife Ventures today.
Bill Sickert brings strong athletic, academic and executive leadership to the NuLife team.
Bill’s passion for multisport competition translated into two World Record performances in the ESPN MET-Rx championships for 1998-99 held at the San Diego Velodrome. Over a decade later, Sickert challenged the field of 1200 athletes at the Spring Sprint Duathlon in San Diego California and won the 2011 championship overall at age 51. 2016 was a monumental win at the RAAM Race Across America as managing crew member for the team that won the race. The experience manifested in 2018 by setting the world record and course record with the team. At 56, he returned to his love of motocross after finding and restoring his original racing bike from 1977. The competitive motorcycle passion returned and led to winning the 2018 Cahuilla Grand Prix in his 450cc class in California.
Tri credentialed in business, law and nutrition; Bill was the recipient of the prestigious West Publishing Award in 1996 for law school academic performance leading to his Summa Cum Laude graduation. The NutraMinder™ newsletter and subsequent blog billsickert.org established his skill at communicating complex health issues in a cogent fashion. Bill has authored the book “WATER” published by Active Interest Media (2008). The publication was chosen by Better Nutrition and reached the bookstands of over 12,000 health food stores nationwide. Bill was also featured in PROSPER Magazine (2010) and Success from Home Magazine (2011).
Sickert commented; “NuLife Ventures brings back my belief in executive fortitude, evidence-based technology and market integrity. My three requirements are people, purpose and integrity and that is why people are attracted to our technology and the company”.
Additional information can be obtained at http://www.billsickert.org or contact Bill directly at 760-421-8255 for research, FDA Clearance and clinical information.
ASD behavior management success related to using the AVACEN 100 has been reported for years by parents who initially purchased the device for themselves and then had their ASD children try it. Improvements range from speech impediments quickly disappearing, to increased classroom participation and enthusiastic homework completion. These encouraging developments have also been accompanied by school grades skyrocketing from D’s to A’s and B’s in just a few months.
According to Gavin Wiswell, a Healthcare Executive from San Marcos California, “Within the first two weeks of using the AVACEN 100 device for 30 minutes, twice a day, my 6-year-old son shocked us by reading a children’s book that he had never read before; from cover to cover, out loud, using his finger to point and perfectly pronounce each word. He typically would recite them back to us from memory, so this was a major breakthrough for our son!”
With approximately 3 million treatments and zero reported adverse effects, the AVACEN 100 is the only known medical device able to safely and noninvasively warm the body rapidly by infusing into the circulatory system using the palm of the hand.
The AVACEN 100 mechanism of action has been thought to mimic the effects of a moderate fever. For over 30 years moderate fever has been recognized as a catalyst for normalizing ASD children for days or even weeks [1] [2]. The Company believes this explains why using the AVACEN 100 daily has been observed to produce in continuous normalization of certain aspects of ASD behavior.
About AVACEN 100 Patents
The US Patent Office has issued 4 Patents to AVACEN. The patents cover innovations embodied in the AVACEN 100 system, which is expected to allow multiple therapeutic uses to alleviate symptoms associated with a circulatory, neurological, lymphatic, or endocrinal dysfunction, or any combination thereof. Patents have also been issued for China, Australia, Japan, UK, France, Germany, Spain, Sweden and Canada. Patents are pending in other countries.
